Drug Approvals and Databases | FDA Downloadable data files FDA Adverse Event Reporting System (FAERS) Public Dashboard Inactive Ingredient Search for Approved Drug Products Search More information Medication Guides Search More
New FDA Drug Approvals for 2026 - Drugs. com Up to date information on the latest FDA drug approvals Includes list of most recent approvals, the conditions approved for, and the approval history
FDA approves 1st non-antipsychotic medication for agitation . . . The Food and Drug Administration (FDA) approved the drug Auvelity this week for the treatment of agitation in adults with Alzheimer's dementia The extended-release tablet is the first FDA-approved medication for this condition that is not an anti-psychotic Anti-psychotics carry serious risks including stroke, sedation and increased death in older adults, according to the FDA Having a non
Travere Therapeutics - Travere Therapeutics Announces Full . . . FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS, marking its expansion beyond IgA nephropathy (IgAN) into a second rare kidney disease FILSPARI is currently the most commonly prescribed FDA-approved medicine for IgAN
FDA Approves Treatment for Serious Liver Disease Known as . . . The U S Food and Drug Administration has approved Wegovy (semaglutide) injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis (excessive scar
FDA Approves Auvelity for Alzheimer Disease-Related Agitation Auvelity was initially approved in 2022 to treat major depressive disorder in adults and is the first nonantipsychotic approved for agitation associated with dementia due to Alzheimer's disease The approval was based on a five-week trial in which participants received either Auvelity or a placebo